Meda To Buy MedPointe

Meda AB, a listed Swedish drug company, has agreed to acquire Somerset, N.J.-based specialty drug company MedPointe Inc. The deal includes $520 million in cash and 17.5 million Meda shares. The stock is currently valued at around $300 million, and represents around 6% of Meda. MedPointe shareholders include The Carlyle Group, Cypress Group, Frazier Healthcare Ventures, Ferrer Freeman & Co. and company management.